Two new meta-analyses confirm what millions of semaglutide and tirzepatide users feared: stop the medication, and most of the weight comes back. A 2025 eClinicalMedicine meta-analysis (18 RCTs, 3,771 participants) found an average regain of 5.63kg after GLP-1 discontinuation, while a second Obesity Reviews analysis pegged semaglutide/tirzepatide regain at 9.69kg within the first year.
Here is exactly what the data shows, why it happens, and four evidence-based strategies to minimize regain if you need to stop.
The Numbers: How Fast Weight Returns
The landmark data comes from the STEP 1 extension trial (Wilding et al., 2022). Participants who lost an average of 17.3% body weight on semaglutide 2.4mg over 68 weeks regained two-thirds of it within one year of stopping. Net weight loss at the 120-week mark: just 5.6%, down from 17.3%.
The newer meta-analyses paint a consistent picture:
| Metric | Finding | Source |
|---|---|---|
| Average regain after semaglutide/tirzepatide | 9.69 kg in year 1 | Berg et al., 2025 |
| Average regain across all GLP-1s | 5.63 kg | eClinicalMedicine meta-analysis |
| Monthly regain rate | ~0.8 kg/month | Pooled analysis |
| Weight retained long-term | ~25% of original loss | Oxford/CNN analysis |
| Liraglutide regain (milder) | 2.20 kg | Berg et al., 2025 |
The pattern is dose-dependent: stronger GLP-1s (semaglutide 2.4mg, tirzepatide) produce more weight loss but also more aggressive regain. Liraglutide users regained significantly less (2.20kg vs 9.69kg), likely because their initial weight loss was smaller.
Beyond weight, the STEP 1 extension showed that improvements in blood pressure, cholesterol, and blood sugar also reversed after discontinuation. This is not just cosmetic -- the metabolic benefits disappear too.
Why Your Body Fights Back
GLP-1 medications do not cure obesity. They manage it. When you remove the drug, the biological drivers that caused weight gain in the first place reassert themselves:
Appetite hormones rebound. Semaglutide suppresses ghrelin (hunger hormone) and enhances satiety signaling through GLP-1 receptors in the brain. Stop the drug, and hunger returns to pre-treatment levels -- often within weeks.
Metabolic rate drops. Weight loss reduces your basal metabolic rate by roughly 15-20 calories per kilogram lost. Your body now burns fewer calories than it did at your starting weight, creating a caloric surplus even at the same intake that maintained your loss.
Set point theory. Your hypothalamus tracks body fat levels and defends a "set point" through hormonal adjustments. GLP-1s override this system. Remove them, and your body actively works to restore its previous fat mass.
Behavioral reversion. People on GLP-1s often do not consciously develop new eating habits because the drug handles appetite suppression. When the drug stops, they lack the learned behaviors needed to maintain the deficit.
What This Means For You: 4 Strategies That Work
If you are on a GLP-1 and considering stopping -- whether for cost, supply issues, side effects, or personal preference -- here is the evidence-based playbook.
1. Taper, Don't Stop Cold
No clinical guideline recommends abrupt discontinuation. Step down your dose over 4-8 weeks. If you are on semaglutide 2.4mg, drop to 1.7mg for a month, then 1.0mg, then 0.5mg before stopping entirely. This gives your appetite hormones time to partially readjust.
For a detailed protocol, read our semaglutide dosing guide.
2. Build the Habits Before You Stop
Start resistance training and high-protein eating (1g protein per pound of lean body mass) while still on the medication. Research shows that participants who established exercise routines during GLP-1 treatment retained significantly more weight loss after stopping. Build the habits when appetite suppression makes it easier, not after.
3. Consider a Maintenance Peptide
Rather than stopping entirely, many providers recommend stepping down to a lower-cost option for long-term maintenance:
- Lower-dose semaglutide (0.25-0.5mg weekly) -- enough to blunt appetite without full therapeutic dosing. Compounded semaglutide at these doses runs $80-150/month.
- Liraglutide -- produces less dramatic results but the Berg meta-analysis showed only 2.20kg regain vs 9.69kg for semaglutide/tirzepatide. A gentler option for maintenance.
- Tesofensine -- a triple monoamine reuptake inhibitor that suppresses appetite through a different mechanism. Some users transition to this for maintenance appetite control. Read our tesofensine dosing guide.
- Retatrutide -- the triple-agonist (GIP/GLP-1/glucagon) that hit 24% weight loss in Phase 2 trials. If you are switching rather than stopping, this is the most potent available option. See our retatrutide dosing guide.
